News News March 14, 2023 Ajinomoto Bio-Pharma Services Awarded Three ‘CDMO Leadership Awards’ Read more February 22, 2023 Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase Read more January 10, 2023 Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer Read more September 26, 2022 Notice of Qualified Invoice Issuer Registration Number GeneDesign, Inc. – Osaka SiteRead more March 3, 2022 Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’ Read more January 25, 2022 Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance Read more January 11, 2022 Notice on email address (for business use) changing Read more November 22, 2021 Notice on email address changing GeneDesign, Inc. – Osaka SiteRead more November 10, 2021 [Reminder] Notice on email address domain changing Read more May 25, 2021 Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity with New Multi-Purpose Fill Suite Read more March 30, 2021 Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing Read more March 29, 2021 Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines Read more Loading…Load More Althea Technologies Announces Expanded Roles for Key Executives Previous Page 1 … 6 7 8